


Sample Screenshots of R&D Drug Pipeline Database as of November 12, 2014



DateiBearbeitenAnsichtChronikLesezeichenExtrasHilfe

La Merie

db.pipelinereview.com/projects

Google

Dear WalFix,
Your account will expire on December 31, 2014.
If you encounter any problems or have questions, please contact us at support@pipelinereview.com

LOGOUTSEARCHEXPORT REPORTSPROJECTS

Projects

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
20732	2014-11-11	FDX-mRNA	Expression of coagulation factor IX	messenger RNA delivered by lipid-enabled LUNAR technology	RNA	Arcturus Therapeutics	United States	Gentourinary, renal & gynecology	Hemophilia B	Preclinical	
20731	2014-11-11	EPO-mRNA	Expression of erythropoietin	messenger RNA delivered by lipid-enabled LUNAR technology	RNA	Arcturus Therapeutics	United States	Gentourinary, renal & gynecology	Anemia	Preclinical	
20729	2014-11-11	RSV-F vaccine (Novavax)	F protein of Respiratory Syncytial Virus (RSV)	Recombinant F-protein micelle vaccine produced in Sf9 insect cells transfected with baculovirus	Vaccine	Novavax	United States	Infectious & toxicology	Prophalaxis of RSV infection in pediatric subjects	I	
20728	2014-11-11	TargomiR	Replacement of tumor suppressor miR-16 via EGF-R targeted delivery	Bacterially derived nanocells packaged with miRNA and guided by bi-specific antibody	RNA	EnGeneIC	Australia	Oncology	Malignant pleural mesothelioma	I	
20727	2014-11-11	Tivantinib; ARQ-197	Selective c-Met inhibitor	Oral small molecule	Small molecule (NCE)	ArQule & Kyowa Hakko Kirin	Japan, United States	Oncology	Metastatic prostate cancer monotherapy	II	
20726	2014-11-11	KTN0158; KTN-0158	KIT receptor antagonist	Rec humanized monoclonal antibody	Antibody	Kolitan & The Children's Hospital of Philadelphia (CHOP)	United States	Pulmonary & respiratory	Allergic asthma	0	
20725	2014-11-11	Grazoprevir and elbasvir; MK-5172/MK-8742; MKS172A	HCV NS3/4a protease inhibitor and HCV NSSA replication complex inhibitor	Fixed-dose combination of two oral small molecules	Small molecule (NCE)	Merck & Co.	United States	Infectious & toxicology	Genotype 1 chronic hepatitis C in combination with sofosbuvir	II	
20724	2014-11-10	Nerofe	Immunomodulation and cytotoxicity	14-mer Peptide IV thrice weekly over 28 day cycle	Peptide	Immune Systems Key	Israel	Oncology	Advanced malignancies	I	
20723	2014-11-10	svL4	C-type lectin receptors	Multi-valent peptide mimetic (MVPM)	Vaccine	Susavion Biosciences	United States	Oncology	Glioblastoma	Preclinical	
20722	2014-11-10	mi-APO	Targeting Hsp70 expressing tumor cells resulting in a specific perforin-independent induction of apoptosis	Recombinant serine protease	Protein	Multimmune	Germany	Oncology	Hsp70-expressing tumors and metastases	Preclinical	

16:00
12.11.2014

Target: All Targets

Technology: All Technologies

All Countries

Aaland Islands

Afghanistan

Albania

Algeria

American Samoa

Andorra

Angola

All Categories

All Therapeutic Areas
Cardiovascular, blood & acute care
Dermatology

All Phases
Market
sBLA

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase
----	-------------	---------	--------	-------------------	----------	---------	-----------	------------------	------------	-------

Projects 0 to 0 of 0

Search

 Print
 Export
 Export

☐ Any Word
 ☐ All Words
 ☐ Exact Phrase
 ☒ Advanced Search

Target:








Technology:

All Countries
Aaland Islands
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola

All Categories
Antibody
Cells

All Therapeutic Areas
Cardiovascular, blood & acute care
Dermatology

All Phases
Market
sBLA

ID	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
20623	2014-10-21	Neihulizumab; AbGn-168H	P-selectin glycoprotein ligand-1 (PSGL-1)	Agonistic rec humanized monoclonal antibody	Antibody	AbGenomics	United States	Dermatology	Psoriatic arthritis	II	
20237	2014-07-31	iCo-008; bertilimumab; CAT-213	Eotaxin-1	Rec fully human IgG4 monoclonal antibody	Antibody	Immune Pharmaceuticals (from iCo Therapeutics, licensed from CAT/MedImmune)	Israel	Dermatology	Bullous pemphigoid	II	
20190	2014-07-17	CHS-0214; etanercept (Coherus)	Tumor necrosis factor (TNF) alpha antagonist	Rec fusion protein, biosimilar of Enbrel (etanercept)	Antibody	Coherus BioSciences & Daiichi Sankyo & Baxter	Japan, United States	Dermatology	Chronic plaque psoriasis	III	
20175	2014-10-21	Dupilumab; SAR231893; SAR-231893; REGN668; REGN-668	Interleukin-4 receptor (IL-4R) antagonist	Rec fully human IgG4 monoclonal antibody (VelocImmune technology)	Antibody	Sanofi & Regeneron	France, United States	Dermatology	Atopic dermatitis	III	
19797	2014-03-22	Humira Pen; adalimumab; ABT-D2E7; LU-200134	TNF alpha antagonist	Rec fully human IgG1 mab	Antibody	AbbVie & Eisai	Japan, United States	Dermatology	Fingernail psoriasis in patients with moderate to severe plaque psoriasis	III	
19732	2014-03-07	STELARA; ustekinumab; CMT0-1275	IL-12 (p40) and IL-23	Rec fully human IgG1 mab (Usticinnab)	Antibody	Johnson & Johnson (Centocor)	United States	Dermatology	Atopic dermatitis	II	
19632	2014-02-10	DLX2751; DLX-2751	Tumor necrosis factor	Single chain antibody (PENTRA	Antibody	Delenex (legacy of	Switzerland	Dermatology	Mild to moderate psoriasis	Preclinical	

DateiBearbeitenAnsichtChronikLesezeichenExtrasHilfe

La Merie

db.pipelinereview.com/projects/search

Google

Technology: All Technologies

Albania
Algeria
American Samoa
Andorra

Therapeutic Area
All Therapeutic Areas
Cardiovascular, blood & acute care

Id	Last Update	Project	Target
19115	2013-09-26	LY3074828; LY-3074828	Interleukin-23 (IL-23) antagonist
18842	2014-02-07	Arzerra, ofatumumab; HuMax-CD20	CD20
18796	2013-07-03	Gevokizumab; XOMA-052; S 78989; S-78989	Interleukin-1 beta (IL-1 beta) antagonist
18794	2014-02-07	GP2015; GP-2015; etanercept biosimilar (Sandoz)	Tumor necrosis factor (TNF) antagonist
18763	2014-11-05	Gevokizumab; XOMA-052; S 78989; S-78989	Interleukin-1 beta (IL-1 beta) antagonist
18443	2014-07-10	ARGX-112	Interleukin-22 receptor (IL-22R) inhibitor
18201	2012-12-15	MABp1	Interleukin-1 alpha (IL-1 alpha) inhibitor
18126	2014-02-10	DLX105; DLX-105 (formerly ESBA105; ESBA-105)	Tumor necrosis factor (TNF) alpha antagonist
18069	2014-02-03	Ustekinumab biosimilar (Harvest Moon)	IL-12 (p40) and IL-23
18030	2012-12-06	Ustekinumab biosimilar (BioXpress)	IL-12 (p40) and IL-23

View Project [18763]

Print

Last Update: 2014-11-05

Gevokizumab; XOMA-052; S 78989; S-78989

Target: Interleukin-1 beta (IL-1 beta) antagonist

Class of Compound: Rec human engineered IgG2 monoclonal antibody

Category: Antibody

Company: XOMA & Les Laboratoires Servier

Territory: France,United States

Therapeutic Area: Dermatology

Indication: Pyoderma gangrenosum

Phase: III

Administration:

Drug Delivery:

Status: Active

Approval US:

Approval UE:

Approval RoW:

Antibody Tech: Human engineering by XOMA technology

Protein Tech:

DNA Tech:

RNA Tech:

Cell Tech:

Vaccine Tech:

Partnering:

News

Date	Title	Comments
2014-11-05	XOMA PR Nov 4, 2014	XOMA announced its pivotal Phase 3 gevokizumab study in patients with active pyoderma gangrenosum (PG), a rare neutrophilic dermatosis of expanding necrotic skin ulcers, is open for patient enrollment. The objective of the study is to assess the efficacy and safety of gevokizumab in treating the active ulcers caused by this rare and debilitating disease
2014-03-05	XOMA PR Mar 4, 2014	XOMA will continue to focus its efforts on completing the EYEGUARD™ Phase 3 clinical program, preparing to initiate its Phase 3 program in patients with pyoderma gangrenosum (PG).
2013-06-14	XOMA PR Jun 13, 2013	It has opened enrollment in a pilot study to determine gevokizumab's potential to treat acute inflammatory pyoderma gangrenosum

Files

No files

Indication	Phase	
Psoriasis	I	
Pemphigus vulgaris (Subcutaneous)	II	
Polymyositis/dermatomyositis	VII	
Moderate to severe chronic plaque-type psoriasis.	II	
Pyoderma gangrenosum	III	
Autoimmune diseases of the skin, including atopic dermatitis, psoriasis and pustular psoriasis.	0	
Acne vulgaris	II	
Mild to moderate psoriasis	IIa	
Moderate to severe psoriasis	Not available	
Moderate to severe psoriasis	Research	

Projects 11 to 20 of 70

16:03
12.11.2014

DateiBearbeitenAnsichtChronikLesezeichenExtrasHilfe

La Merie

db.pipelinereview.com/projects/search

Google

La Merie
Business Intelligence

Dear WalFix,
Your account will expire on December 31, 2014.
If you encounter any problems or have questions, please contact us at support@pipelinereview.com

LOGOUTSEARCHEXPORT REPORTSPROJECTS

Search

SearchClear

Any WordAll WordsExact PhraseAdvanced Search

Target: All Targets

Techno: RANKL Antibodies: Biosimilars and Biosuperiors
Ras-Raf-MEK-ERK Inhibitors
Rituximab (Rituxan/MabThera) Biosimilars
RNA Therapeutics in Clinical Development
RSV Antibodies: Biosimilars and Biosuperiors
RSV Vaccines & Therapeutics
S. aureus: Biologic and Immune Therapy
Sales of Antibodies and Proteins in 2013
Selective Estrogen Receptor Modulators
SGLT Inhibitors

Territory

All Countries
Aaland Islands
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola

Category

All Categories
Antibody
Cells

Therapeutic Area

All Therapeutic Areas
Cardiovascular, blood & acute care
Dermatology

Phase

All Phases
Market
sBLA

Id	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase		
20732	ssenger RNA delivered by s-enabled LUNAR technology	RNA	Arcturus Therapeutics	United States	Gentourinary, renal & gynecology	Hemophilia B	Preclinical		
20731	ssenger RNA delivered by s-enabled LUNAR technology	RNA	Arcturus Therapeutics	United States	Gentourinary, renal & gynecology	Anemia	Preclinical		
20729	combinant F-protein micelle vaccine produced in Sf9 insect cells transfected with baculovirus	Vaccine	Novavax	United States	Infectious & toxicology	Prophalaxis of RSV infection in pediatric subjects	I		
20728	Replacement of tumor suppressor miR-16 via EGF-R targeted delivery	Bacterially derived nanocells packaged with miRNA and guided by bi-specific antibody	EnGeneIC	Australia	Oncology	Malignant pleural mesothelioma	I		
20727	2014-11-11 Tivantinib; ARQ-197	Selective c-Met inhibitor	Oral small molecule	Small molecule (NCE)	ArQule & Kyowa Hakko Kirin	Japan, United States	Oncology	Metastatic prostate cancer monotherapy	II
20726	2014-11-11 KTN0158; KTN-0158	KIT receptor antagonist	Rec humanized monoclonal antibody	Antibody	Kolitan & The Children's Hospital of Philadelphia (CHOP)	United States	Pulmonary & respiratory	Allergic asthma	0
	2014-11-11 Grazoprevir and elbasvir	HCV NS3/4a protease inhibitor and HCV NS5A	Fixed-dose combination of two					Genotype 1 chronic	

PrintExportExport

16:05
12.11.2014

DateiBearbeitenAnsichtChronikLesezeichenExtrasHilfe

La Merie

db.pipelinereview.com/projects/search

Google

La Merie
Business Intelligence

Dear WalFix,
Your account will expire on December 31, 2014.
If you encounter any problems or have questions, please contact us at support@pipelinereview.com

LOGOUTSEARCHEXPORT REPORTSPROJECTS

Search

SearchClear

☐ Any Word☐ All Words☐ Exact Phrase☐ Advanced Search

Target: Sales of Antibodies and Proteins in 2013

Technology: All Technologies

Territory

All Countries
Aaland Islands
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola

Category

All Categories
Antibody
Cells

Therapeutic Area

All Therapeutic Areas
Cardiovascular, blood & acute care
Dermatology

Phase

All Phases
Market
sBLA

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
20512	2014-09-29	G-Lasta; pegfilgrastim	Granulocyte colony stimulating factor (G-CSF) receptor agonist	Pegylated rec methionyl human G-CSF	Protein	Kyowa Hakkio Kirin (from Kirin-Amgen)	Japan	Oncology	Febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy	Market	
19750	2014-03-14	NovoRapid; insulin aspart	Insulin receptor	Rhu insulin analog aspart, available in pen	Protein	Novo Nordisk	Denmark	Metabolism & endocrine	Type 1 and 2 diabetes	Market	
18473	2014-03-13	NESP; darbepoetin	Erythropoietin receptor (EPO-R) agonist	Rhu glycoengineered protein	Protein	Kyowa Hakkio Kirin Pharma (from Amgen)	Japan	Genitourinary, renal & gynecology	Renal anemia	Market	
17157	2014-03-12	SOMAVERT; pegvisomant	Growth hormone (GH) receptor antagonist	PEGylated rhu protein of 191 aa produced in E. coli	Protein	Pfizer	United States	Metabolism & endocrine	Acromegaly	Market	
12553	2014-03-03	Yervoy; ipilimumab; MDX-010; BMS-734016	CTLA-4 (CD152); thereby inhibition of B7-CTLA-4-mediated downregulation of T-cell activation	Rec fully human IgG1 monoclonal antibody	Antibody	Bristol-Myers Squibb (BMS, acquired Medarex)	United States	Oncology	Locally advanced or unresectable or metastatic melanoma	Market	

Gazvwa (US) / Gazvvaro (EU):

Glycoengineered rec humanized

Roche (GlycArt

Front-line chronic

16:06
12.11.2014

CD20 bispecific

☐ Any Word ☒ All Words ☐ Exact Phrase ☐ Advanced Search

Target:

Technology:






Territory

- All Countries
- Aland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

Category

Therapeutic Area

Phase

ID	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
19638	2014-02-11	CD20-CD3 Bispecific antibody (Regeneron=	CD20 tumor targeting and CD3 for T cell recruitment (intact Fc recruits accessory cells)	Rec fully human monoclonal antibody (modified Velocimmune mice)	Antibody	Regeneron Pharmaceuticals	United States	Oncology	B cell lymphoma	0	
19562	2014-01-27	Novotarg	CD20 and CD95	Rec bispecific monoclonal antibody	Antibody	Baliopharm (spin-off from Celonic)	Switzerland	Neurology & psychiatry	Multiple sclerosis	Research	
16794	2012-10-18	20-(74)-(74)	CD20 and CD74	Hexavalent dock-and-Lock-engineered antibody (DNL) linked to 4 antigen-binding regions (Fabs) of veltuzumab linked to an intact milatuzumab	Antibody	Immunomedics	United States	Oncology	Mantle cell lymphoma (MCL)	Preclinical	
10446	2012-10-08	CD79bXDR SCORPION	CD79B (B-cell) and HLA-DR	Single-chain, bispecific antibody construct	Antibody	Emergent Biosolutions (acquired Trubion Pharmaceuticals)	United States	Oncology	B-cell lymphoma	Preclinical	
2285	2014-11-11	Lymphomun; FBTA-05; FBTA05	CD20 tumor targeting and CD3 for T cell recruitment (intact Fc recruits accessory cells)	Trifunctional rec bispecific mouse/rat IgG2 antibody (Triomab)	Antibody	Lindis Biotech (from TRION Pharma)	Germany	Oncology	B cell lymphoma	III	

Projects 1 to 10 of 5

Export Reports

Print Export Export

Date:  to:  Custom Report  Search Clear

Territory

- All Countries
- Aaland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

Target:

All Targets

Technology:
All Technologies

Category

Therapeutic Area

Phase

IIIa
III
IIIb/II

Keyword
psoriasis
☒ Any Word ☐ All Words ☐ Exact Phrase

ID	Project	Target	Class of Compound	Company	Category	Indication	R&D Stage	Message
1569	Tidrakizumab; MK-3222; SCH 900222	Selective interleukin-23 (IL-23) inhibitor via p19	Rec humanized IgG1 monoclonal antibody	Sun Pharma (from Merck & Co. / acquired Schering-Plough)	Antibody	Psoriasis	III	
10241	Brodalumab; AMG-827; AMG 827; KHK4827; KHK-4827	Interleukin-17 receptor (IL-17R)	Rec fully human IgG2 mab given SC	Amgen & AstraZeneca & Kyowa Hakko Kirin	Antibody	Moderate to severe plaque psoriasis	III	
10970	Guselkumab; CNTO 1959; CNTO-1959	p19 subunit of interleukin-23 (IL-23)	Rec fully human HuCAL full mab	Janssen Research & Development (Johnson & Johnson; Centocor)	Antibody	Moderate to severe psoriasis	III	
16654	Ixekizumab; LY2439821; LY-2439821	Interleukin-17 (IL-17) antagonist	Rec humanized IgG4 monoclonal antibody with SC dosing	Eli Lilly	Antibody	Psoriasis	III	
18346	ABP 501; ABP-501	Tumor necrosis factor (TNF) inhibitor	Rec fully human mab. Biosimilar of Humira (adalimumab). SC in prefille syringe	Amgen	Antibody	Rheumatoid arthritis and plaque psoriasis	III	

DateiBearbeitenAnsichtChronikLesezeichenExtrasHilfe

La Merie

db.pipelinereview.com/projects/reports

Google

La Merie
Business Intelligence

Dear WalFix,
Your account will expire on December 31, 2014.
If you encounter any problems or have questions, please contact us at support@pipelinereview.com

LOGOUTSEARCHEXPORT REPORTSPROJECTS

Export Reports

PrintExportExport

Date:to:Custom ReportSearchClear

Territory

All Countries
Aaland Islands
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola

Target:

All Targets

Technology:

All Technologies

Keyword

psoriasis

☒ Any Word☐ All Words☐ Exact Phrase

Category

All Categories
Antibody
Cells

Therapeutic Area

All Areas
Cardiovascular, blood & acute care
Dermatology

Phase

Ila
II
IIb/III

ID	Project	Target	Class of Compound	Company	Category		
1569	Tildrakizumab; MK-3222; SCH 900222	Selective interleukin-23 (IL-23) inhibitor via p19	Rec humanized IgG1 monoclonal antibody	Sun Pharma (from Merck & Co. / acquired Schering-Plough)	Antibody	Psoriasis	III
10241	Brodalumab; AMG-827; AMG 827; KHK4827; KHK-4827	Interleukin-17 receptor (IL-17R)	Rec fully human IgG2 mab given SC	Amgen & AstraZeneca & Kyowa Hakko Kirin	Antibody	Moderate to severe plaque psoriasis	III
10970	Guselkumab; CNTO 1959; CNTO-1959	p19 subunit of interleukin-23 (IL-23)	Rec fully human HuCAL full mab	Janssen Research & Development (Johnson & Johnson; Centocor)	Antibody	Moderate to severe psoriasis	III
16654	bekizumab; LY2439821; LY-2439821	Interleukin-17 (IL-17) antagonist	Rec humanized IgG4 monoclonal antibody with SC dosing	Eli Lilly	Antibody	Psoriasis	III
18346	ABP 501; ABP-501	Tumor necrosis factor (TNF) inhibitor	Rec fully human mab. Biosimilar of Humira (adalimumab). SC in prefile syringe	Amgen	Antibody	Rheumatoid arthritis and plaque psoriasis	III

Öffnen von projects.doc

Sie möchten folgende Datei öffnen:
projects.doc
Vom Typ: Microsoft Word 97 - 2003 Document
Von: http://db.pipelinereview.com
Wie soll Firefox mit dieser Datei verfahren?
☒ Öffnen mit Microsoft Word (Standard)
☐ Datei speichern
☐ Für Dateien dieses Typs immer diese Aktion ausführen
OKAbbrechen

16:09
12.11.2014

Date: to: Custom Report

Territory

All Countries
Aaland Islands
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola

Target:

All Targets

Technology:

All Technologies

Category:

All Categories
Antibody
Cells

Therapeutic Area

All Areas
Cardiovascular, blood & acute care
Dermatology

Phase:

IIa
II
IIb/III

ID	Project	Target	Class of Compound
1569	Tildrakizumab; MK-3222; SCH 900222	Selective interleukin-23 (IL-23) inhibitor via p19	Rec humanized IgG antibody
10241	Brodalumab; AMG-827; AMG 827; KHK4827; KHK-4827	Interleukin-17 receptor (IL-17R)	Rec fully human IgG
10970	Guselkumab; CNTO 1959; CNTO-1959	p19 subunit of interleukin-23 (IL-23)	Rec fully human IgG
16654	Ikekizumab; LY2439821; LY-2439821	Interleukin-17 (IL-17) antagonist	Rec humanized IgG antibody with SC
18346	ABP 501; ABP-501	Tumor necrosis factor (TNF) inhibitor	Rec fully human IgG Humira (adalimumab) syringe